For the quarter ending 2025-09-30, TRVI had -$60,189K decrease in cash & cash equivalents over the period. -$10,892K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Chronic cough in ipf clinical trial expense | 822 | - |
| Refractory chronic cough clinical trial expense | 119 | - |
| Clinical trial material | 5,058 | - |
| Other clinical trials and studies | 27 | - |
| Other clinical development expenses | 1,548 | - |
| Employee compensation (excluding stock compensation expense) | 3,041 | - |
| Stock-based compensation expense | 1,243 | - |
| Other segment items | 2,045 | - |
| Interest income, net | 2,101 | - |
| Net loss | -11,802 | -22,641 |
| Stock-based compensation | 1,243 | 2,592 |
| Operating lease right-of-use assets | 108 | 222 |
| Depreciation and amortization | 38 | 75 |
| Accretion of available-for-sale marketable securities, net | 298 | 778 |
| Prepaid expenses and other current assets | 30 | 1,606 |
| Accrued expenses and other liabilities | 143 | -1,003 |
| Accounts payable | -282 | -439 |
| Net cash used in operating activities | -10,880 | -23,578 |
| Proceeds from maturities of available-for-sale marketable securities | 20,684 | 32,095 |
| Purchases of available-for-sale marketable securities | 71,610 | 44,656 |
| Purchases of property, equipment and leasehold improvements | 12 | 0 |
| Net cash (used in) provided by investing activities | -50,938 | -12,561 |
| Proceeds from offering of common stock, net of commissions | 0 | 108,154 |
| Proceeds from exercises of warrants | 0 | 10,757 |
| Proceeds from exercises of stock options | 1,123 | 731 |
| Proceeds from disgorgement of beneficial owner's short-swing profits | 725 | - |
| Proceeds from employee stock purchase plan | 0 | 59 |
| Payments of offering costs | 219 | 590 |
| Payments of finance lease | 0 | 11 |
| Proceeds from at-the-market sales agreement, net of commissions and allocated fees | 0 | 0 |
| Net cash provided by financing activities | 1,629 | 119,100 |
| Net increase (decrease) in cash and cash equivalents | -60,189 | 82,961 |
| Cash and cash equivalents at beginning of period | 34,097 | - |
| Cash and cash equivalents at end of period | 56,869 | - |
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)